Adaptive Biotechnologies (ADPT) Capital Expenditures (2018 - 2026)

Adaptive Biotechnologies has disclosed Capital Expenditures across 9 years of filings, most recently posting $1.2 million for Q2 2026.

• In Q2 2026, Capital Expenditures rose 80.76% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $3.0 million (up 29.38% YoY), while the FY2025 annual figure was $3.0 million, down 19.24% from the prior year.
• Capital Expenditures came in at $1.2 million for Q2 2026 at Adaptive Biotechnologies, up from $796000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $5.4 million in Q3 2022 to a low of $80000.0 in Q4 2024.
• Average Capital Expenditures over 5 years is $2.0 million, with a median of $1.4 million recorded in 2023.
• Year-over-year, Capital Expenditures tumbled 93.84% in 2024 and jumped 695.0% in 2025.
• Over 5 years, Capital Expenditures stood at $2.5 million in 2022, then slumped by 48.94% to $1.3 million in 2023, then plunged by 93.84% to $80000.0 in 2024, then jumped by 695.0% to $636000.0 in 2025, then surged by 86.16% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $1.2 million in Q2 2026, $796000.0 in Q1 2026, and $636000.0 in Q4 2025.